GB0424959D0 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
GB0424959D0
GB0424959D0 GB0424959A GB0424959A GB0424959D0 GB 0424959 D0 GB0424959 D0 GB 0424959D0 GB 0424959 A GB0424959 A GB 0424959A GB 0424959 A GB0424959 A GB 0424959A GB 0424959 D0 GB0424959 D0 GB 0424959D0
Authority
GB
United Kingdom
Prior art keywords
novel compounds
novel
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GB0424959A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to GB0424959A priority Critical patent/GB0424959D0/en
Publication of GB0424959D0 publication Critical patent/GB0424959D0/en
Priority to MX2007005776A priority patent/MX2007005776A/es
Priority to RU2007121581/04A priority patent/RU2007121581A/ru
Priority to BRPI0517792-8A priority patent/BRPI0517792A/pt
Priority to US11/719,004 priority patent/US7718621B2/en
Priority to EP05801894A priority patent/EP1824870A1/en
Priority to JP2007540573A priority patent/JP2008519788A/ja
Priority to CNA2005800463765A priority patent/CN101098881A/zh
Priority to TW094139277A priority patent/TW200630378A/zh
Priority to PE2005001311A priority patent/PE20061137A1/es
Priority to ARP050104704A priority patent/AR053311A1/es
Priority to AU2005303961A priority patent/AU2005303961A1/en
Priority to CA002587413A priority patent/CA2587413A1/en
Priority to PCT/EP2005/012038 priority patent/WO2006050942A1/en
Priority to KR1020077012942A priority patent/KR20070085919A/ko
Priority to US12/093,145 priority patent/US20080269146A1/en
Priority to IL182978A priority patent/IL182978A0/en
Priority to ZA200703603A priority patent/ZA200703603B/en
Priority to MA29930A priority patent/MA29213B1/fr
Priority to NO20072939A priority patent/NO20072939L/no
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
GB0424959A 2004-11-11 2004-11-11 Novel compounds Ceased GB0424959D0 (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
GB0424959A GB0424959D0 (en) 2004-11-11 2004-11-11 Novel compounds
KR1020077012942A KR20070085919A (ko) 2004-11-11 2005-11-09 마크로론 - 아미노 치환된 퀴놀론
TW094139277A TW200630378A (en) 2004-11-11 2005-11-09 Macrolones-amino substituted quinolones
ARP050104704A AR053311A1 (es) 2004-11-11 2005-11-09 Macrolonas - quinolonas amino sustituidas
BRPI0517792-8A BRPI0517792A (pt) 2004-11-11 2005-11-09 macrolonas - quinolonas amino-substituìdas
US11/719,004 US7718621B2 (en) 2004-11-11 2005-11-09 Macrolones—amino substituted quinolones
EP05801894A EP1824870A1 (en) 2004-11-11 2005-11-09 Macrolones - amino substituted quinolones
JP2007540573A JP2008519788A (ja) 2004-11-11 2005-11-09 マクロロン−アミノ置換キノロン
CNA2005800463765A CN101098881A (zh) 2004-11-11 2005-11-09 大环内酯-氨基取代的2-羟基喹啉
MX2007005776A MX2007005776A (es) 2004-11-11 2005-11-09 Macrolonas-quinolonas amino sustituidas.
PE2005001311A PE20061137A1 (es) 2004-11-11 2005-11-09 Compuestos derivados de macrolidos amino sustituidas
RU2007121581/04A RU2007121581A (ru) 2004-11-11 2005-11-09 Макролоны-аминозамещенные хинолоны
AU2005303961A AU2005303961A1 (en) 2004-11-11 2005-11-09 Macrolones - Amino substituted quinolones
CA002587413A CA2587413A1 (en) 2004-11-11 2005-11-09 Macrolones - amino substituted quinolones
PCT/EP2005/012038 WO2006050942A1 (en) 2004-11-11 2005-11-09 Macrolones - amino substituted quinolones
US12/093,145 US20080269146A1 (en) 2004-11-11 2006-11-07 4''-Substituted Erythromycin Derivative
IL182978A IL182978A0 (en) 2004-11-11 2007-05-03 Macrolones-amino substituted quinolones
ZA200703603A ZA200703603B (en) 2004-11-11 2007-05-04 Macrolones - amino substituted quinolones
MA29930A MA29213B1 (fr) 2004-11-11 2007-05-22 Quinolones a substitution macrolones - amino
NO20072939A NO20072939L (no) 2004-11-11 2007-06-08 Makroloner - aminosubstituerte kinoloner

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0424959A GB0424959D0 (en) 2004-11-11 2004-11-11 Novel compounds

Publications (1)

Publication Number Publication Date
GB0424959D0 true GB0424959D0 (en) 2004-12-15

Family

ID=33523587

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0424959A Ceased GB0424959D0 (en) 2004-11-11 2004-11-11 Novel compounds

Country Status (19)

Country Link
US (2) US7718621B2 (enExample)
EP (1) EP1824870A1 (enExample)
JP (1) JP2008519788A (enExample)
KR (1) KR20070085919A (enExample)
CN (1) CN101098881A (enExample)
AR (1) AR053311A1 (enExample)
AU (1) AU2005303961A1 (enExample)
BR (1) BRPI0517792A (enExample)
CA (1) CA2587413A1 (enExample)
GB (1) GB0424959D0 (enExample)
IL (1) IL182978A0 (enExample)
MA (1) MA29213B1 (enExample)
MX (1) MX2007005776A (enExample)
NO (1) NO20072939L (enExample)
PE (1) PE20061137A1 (enExample)
RU (1) RU2007121581A (enExample)
TW (1) TW200630378A (enExample)
WO (1) WO2006050942A1 (enExample)
ZA (1) ZA200703603B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1638549A4 (en) 2003-03-10 2011-06-15 Optimer Pharmaceuticals Inc NEW ANTIBACTERIAL AGENTS
EP1879904A1 (en) * 2005-05-10 2008-01-23 GlaxoSmithKline istrazivacki centar Zagreb d.o.o. 4" amino linked macrolides useful for the treatment of microbial infections
EP1951735A1 (en) * 2005-11-09 2008-08-06 Glaxo Group Limited New 4*-substituted erythromycin derivative
EP1945652A1 (en) * 2005-11-09 2008-07-23 Glaxo Group Limited Macrolones
JP5461405B2 (ja) 2007-09-14 2014-04-02 バーテックス ファーマシューティカルズ インコーポレイテッド 嚢胞性線維症膜コンダクタンス制御因子の調節因子
US9453042B2 (en) 2007-10-25 2016-09-27 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
TW200946109A (en) * 2008-05-09 2009-11-16 Enanta Pharm Inc Anti-bacterial activity of 9-hydroxy derivatives 6, 11-bicyclolides
HRP20160222T1 (hr) 2008-10-24 2016-04-08 Cempra Pharmaceuticals, Inc. Biozaštite uporabom makrolida koji sadrže triazol
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
EP2475253B1 (en) 2009-09-10 2016-10-26 Cempra Pharmaceuticals, Inc. Methods for treating malaria, tuberculosis and mac diseases
CN102917708B (zh) 2010-05-20 2015-11-25 森普拉制药公司 制备大环内酯和酮内酯及其中间体的方法
US9815863B2 (en) 2010-09-10 2017-11-14 Cempra Pharmaceuticals, Inc. Hydrogen bond forming fluoro ketolides for treating diseases
IN2014DN08939A (enExample) 2012-03-27 2015-05-22 Cempra Pharmaceuticals Inc
CA2905975A1 (en) 2013-03-14 2014-09-25 Cempra Pharmaceuticals, Inc. Methods for treating respiratory diseases and formulations therefor
EP2968384A4 (en) 2013-03-15 2017-02-15 Cempra Pharmaceuticals, Inc. Convergent processes for preparing macrolide antibacterial agents
CN106589023A (zh) * 2016-11-22 2017-04-26 宜昌东阳光药业股份有限公司 一种罗红霉素杂质及其合成方法
WO2018178041A1 (en) 2017-03-30 2018-10-04 F. Hoffmann-La Roche Ag Novel pyrido[2,3-b]indole compounds for the treatment and prophylaxis of bacterial infection

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2808070A1 (de) * 1978-02-24 1979-08-30 Bayer Ag Verfahren zur herstellung von 4-pyridon-3-carbonsaeuren und/oder deren derivaten
GB0127349D0 (en) * 2001-11-14 2002-01-02 Glaxo Group Ltd Macrolides
GB0225384D0 (en) * 2002-10-31 2002-12-11 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
ZA200703603B (en) 2008-07-30
BRPI0517792A (pt) 2008-10-21
NO20072939L (no) 2007-08-08
TW200630378A (en) 2006-09-01
CN101098881A (zh) 2008-01-02
US7718621B2 (en) 2010-05-18
WO2006050942A1 (en) 2006-05-18
PE20061137A1 (es) 2006-12-13
RU2007121581A (ru) 2008-12-20
CA2587413A1 (en) 2006-05-18
KR20070085919A (ko) 2007-08-27
MX2007005776A (es) 2007-07-16
AR053311A1 (es) 2007-05-02
AU2005303961A1 (en) 2006-05-18
IL182978A0 (en) 2007-08-19
EP1824870A1 (en) 2007-08-29
MA29213B1 (fr) 2008-02-01
US20080269146A1 (en) 2008-10-30
JP2008519788A (ja) 2008-06-12
US20080090773A1 (en) 2008-04-17

Similar Documents

Publication Publication Date Title
GB0409744D0 (en) Novel compounds
EP1718638A4 (en) NEW COMPOUNDS
GB0405628D0 (en) Novel compounds
GB0402140D0 (en) Novel compounds
GB0402496D0 (en) Novel compounds
GB0402357D0 (en) Novel compounds
GB0424959D0 (en) Novel compounds
EP1805132A4 (en) NEW COMPOUNDS
GB0424958D0 (en) Novel compounds
GB0408083D0 (en) Novel compounds
EP1796793A4 (en) NEW CONNECTIONS
GB0402355D0 (en) Novel compounds
GB0402812D0 (en) Novel compounds
GB0402356D0 (en) Novel compounds
GB0424951D0 (en) Novel compounds
GB0402380D0 (en) Novel compounds
GB0404105D0 (en) Novel compounds
GB0424961D0 (en) Novel compounds
GB0408445D0 (en) Novel compounds
GB0408444D0 (en) Novel compounds
GB0406030D0 (en) Novel compounds
GB0406029D0 (en) Novel compounds
GB0406027D0 (en) Novel compounds
GB0406032D0 (en) Novel compounds
GB0404579D0 (en) Novel compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)